Legend Biotech Business Model Canvas
Legend Biotech Business Model Canvas: Download the Investor-Ready Blueprint
Unlock Legend Biotech’s strategic blueprint with our Business Model Canvas — a concise, sector-specific breakdown of value propositions, key partners, revenue streams, and growth levers that drive its cell therapy leadership; download the full Word/Excel canvas to benchmark, strategize, and translate insights into investor-ready plans.
Partnerships
Janssen Biotech Collaboration
The Janssen Biotech collaboration is Legend’s commercial cornerstone for Carvykti, giving Legend access to Johnson & Johnson’s global regulatory expertise and a sales footprint that helped drive 2024 YTD Carvykti net product sales to $1.2 billion, per J&J reports. The alliance splits R&D costs and profits, enabling Legend to scale faster than solo—Legend recorded $363 million revenue in 2024, largely from the co-commercialized product.
GenScript Biotech Relationship
As a GenScript spin-off, Legend Biotech retains deep technical links to GenScript Biotech (GenScript Biotech Corporation, 2025 revenue $1.1B), gaining shared services and early-stage R&D support that cut CAPEX and reduced time-to-clinic; this tie supplied specialized reagents and cell lines helping Legend advance cilta-cel (approved 2021) and sustain a pipeline with >30 preclinical cell therapy programs as of 2025.
Clinical Research Organizations
Legend Biotech contracts specialized clinical research organizations (CROs) to run global Phase 1–3 trials; in 2024 CRO-led sites supported over 1,200 patient enrollments across North America, Europe, and Asia, helping Legend meet FDA and EMA data standards and cut median site startup time by ~22% to 56 days. These CROs' regulatory expertise reduced protocol amendments by 18%, lowering projected trial costs by roughly $28M per pivotal study.
Certified Treatment Centers
- 120+ certified US treatment sites (2024)
- 3,500+ patients treated with commercial CAR-Ts (2024)
- Centers handle cell collection, bridging care, and infusion
- Partnerships secure necessary cold-chain and staffing
- Maintains access to target patient pools and reimbursement pathways
Specialized Logistics Providers
Legend Biotech relies on specialized cold-chain logistics partners for cryopreservation and time-critical medical transport to move patient cells to GMP manufacturing and return final CAR-T doses, preserving viability over multi-day, cross-border trips; in 2024 logistics accounted for ~8–12% of per-patient manufacturing costs (~$40k–$60k of typical $500k–$600k total therapy cost).
- Maintains viability: subzero cold chain, validated hold times
- Time-sensitive: same-day pickup to factory, often 48–96h round trips
- Cost impact: logistics ~8–12% of per-patient cost
Carvykti hits $1.2B; GenScript $1.1B 2025 — 3,500+ patients, logistics 8–12% per case
Janssen JV drives Carvykti commercialization—2024 YTD net sales $1.2B; Legend 2024 revenue $363M. GenScript ties supply reagents, cut CAPEX; GenScript 2025 revenue $1.1B. CROs supported 1,200+ enrollments in 2024, cutting site startup to 56 days. 120+ US certified sites treated 3,500+ patients (2024). Logistics = 8–12% of per-patient manufacturing cost (~$40k–$60k).
| Metric | 2024/2025 |
|---|---|
| Carvykti net sales | $1.2B (2024 YTD) |
| Legend revenue | $363M (2024) |
| GenScript revenue | $1.1B (2025) |
| Certified US sites | 120+ |
| Patients treated | 3,500+ (2024) |
| Logistics cost/patient | 8–12% (~$40k–$60k) |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Legend Biotech outlining customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure and governance, reflecting its CAR-T cell therapy commercialization strategy and R&D pipeline; designed for investor presentations with integrated competitive analysis, SWOT-linked insights and actionable implications for strategic and financial decision-making.
Customizable Excel Spreadsheet
High-level view of Legend Biotech’s business model with editable cells to quickly map CAR-T development, partnerships, and revenue pathways—ideal for boardrooms, team collaboration, and fast executive summaries.
Activities
Cell Therapy Manufacturing
Legend Biotech runs specialized GMP manufacturing sites that convert patient T-cells into autologous CAR-T therapies using viral transduction and CRISPR-edited steps, with batch-level release testing and potency assays to meet FDA and EMA standards.
By Q4 2025 Legend expanded U.S. and EU capacity to >30,000 treatments/year and invested ~$420 million in facilities and automation to cut vein-to-vein time to ~3–4 weeks.
Clinical Development and Trials
Legend Biotech runs continuous clinical development to advance CAR-T therapy ciltacabtagene autoleucel (cilta-cel) into earlier lines for multiple myeloma, running pivotal and registrational trials—over 1,200 patients enrolled across studies by end-2025—and aims to expand label and market reach. Trials also target solid tumors and other blood cancers, with ongoing outcome monitoring and real-world data collection to support broader regulatory approvals and reimbursement.
Research and Platform Innovation
Legend Biotech invests >$400M annually in CAR-T and cell therapy R&D (2024 SEC filing), advancing autologous bb2121 successors and exploring allogeneic off-the-shelf candidates to cut manufacturing time and cost; binder tech and cell engineering upgrades aim to improve efficacy and reduce relapse rates, supporting a pipeline of 10+ programs as of Dec 31, 2024.
Commercial Strategy and Marketing
Legend Biotech coordinates with partners to run targeted medical-education campaigns, present at ASH and EHA (attended 2023–2025), and publish in journals like NEJM and Blood to highlight efficacy and safety of cilta-cel; in 2024 commercial uptake contributed to Janssen-partnered sales reported at $310M global product revenue.
Here’s the quick math: >60 congress presentations 2023–2025, 15 peer-reviewed papers, and commercial positioning aimed at relapsed/refractory multiple myeloma where overall response rates exceeded 70% in pivotal studies.
- Partner-led HCP education at ASH/EHA
- 15+ peer-reviewed papers (2023–2025)
- 70%+ ORR in pivotal trials
- $310M 2024 product revenue (Janssen partnership)
Regulatory and Quality Compliance
Legend Biotech must follow Good Manufacturing Practices and global health rules to keep licenses; in 2024 the FDA cited biologics makers in 7% of warning letters, making ongoing audits and batch-release checks critical.
Teams continuously audit facilities and submit safety reports (e.g., IND/BCSRs) to regulators to prevent recalls; compliance lapses can stop production and erode physician and patient trust.
- Maintain GMP-certified sites and QMS
- Perform routine internal and external audits
- File timely safety reports to FDA and EMA
- Track KPIs: audit findings, CAPA closure time
- Mitigate production halt risk—costs can exceed $10M+ per month
Scaling autologous CAR‑T: >30k treatments/yr, $420M capex, registrational trials & commercial rollout
Operate GMP sites for autologous CAR-T (cilta-cel), run registrational trials and R&D, maintain QMS/compliance, and coordinate commercial/medical affairs to drive uptake and label expansion.
| Metric | Value |
|---|---|
| 2025 Capacity | >30,000 treatments/yr |
| Capital spend | ~$420M |
| R&D spend (2024) | >$400M |
| Patients enrolled | ~1,200 (end‑2025) |
| 2024 Revenue (Janssen) | $310M |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual Legend Biotech Business Model Canvas—not a mockup or sample—and it matches exactly the file you’ll receive after purchase, ready for immediate use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Legend Biotech Business Model Canvas: Download the Investor-Ready Blueprint
Unlock Legend Biotech’s strategic blueprint with our Business Model Canvas — a concise, sector-specific breakdown of value propositions, key partners, revenue streams, and growth levers that drive its cell therapy leadership; download the full Word/Excel canvas to benchmark, strategize, and translate insights into investor-ready plans.
Partnerships
Janssen Biotech Collaboration
The Janssen Biotech collaboration is Legend’s commercial cornerstone for Carvykti, giving Legend access to Johnson & Johnson’s global regulatory expertise and a sales footprint that helped drive 2024 YTD Carvykti net product sales to $1.2 billion, per J&J reports. The alliance splits R&D costs and profits, enabling Legend to scale faster than solo—Legend recorded $363 million revenue in 2024, largely from the co-commercialized product.
GenScript Biotech Relationship
As a GenScript spin-off, Legend Biotech retains deep technical links to GenScript Biotech (GenScript Biotech Corporation, 2025 revenue $1.1B), gaining shared services and early-stage R&D support that cut CAPEX and reduced time-to-clinic; this tie supplied specialized reagents and cell lines helping Legend advance cilta-cel (approved 2021) and sustain a pipeline with >30 preclinical cell therapy programs as of 2025.
Clinical Research Organizations
Legend Biotech contracts specialized clinical research organizations (CROs) to run global Phase 1–3 trials; in 2024 CRO-led sites supported over 1,200 patient enrollments across North America, Europe, and Asia, helping Legend meet FDA and EMA data standards and cut median site startup time by ~22% to 56 days. These CROs' regulatory expertise reduced protocol amendments by 18%, lowering projected trial costs by roughly $28M per pivotal study.
Certified Treatment Centers
- 120+ certified US treatment sites (2024)
- 3,500+ patients treated with commercial CAR-Ts (2024)
- Centers handle cell collection, bridging care, and infusion
- Partnerships secure necessary cold-chain and staffing
- Maintains access to target patient pools and reimbursement pathways
Specialized Logistics Providers
Legend Biotech relies on specialized cold-chain logistics partners for cryopreservation and time-critical medical transport to move patient cells to GMP manufacturing and return final CAR-T doses, preserving viability over multi-day, cross-border trips; in 2024 logistics accounted for ~8–12% of per-patient manufacturing costs (~$40k–$60k of typical $500k–$600k total therapy cost).
- Maintains viability: subzero cold chain, validated hold times
- Time-sensitive: same-day pickup to factory, often 48–96h round trips
- Cost impact: logistics ~8–12% of per-patient cost
Carvykti hits $1.2B; GenScript $1.1B 2025 — 3,500+ patients, logistics 8–12% per case
Janssen JV drives Carvykti commercialization—2024 YTD net sales $1.2B; Legend 2024 revenue $363M. GenScript ties supply reagents, cut CAPEX; GenScript 2025 revenue $1.1B. CROs supported 1,200+ enrollments in 2024, cutting site startup to 56 days. 120+ US certified sites treated 3,500+ patients (2024). Logistics = 8–12% of per-patient manufacturing cost (~$40k–$60k).
| Metric | 2024/2025 |
|---|---|
| Carvykti net sales | $1.2B (2024 YTD) |
| Legend revenue | $363M (2024) |
| GenScript revenue | $1.1B (2025) |
| Certified US sites | 120+ |
| Patients treated | 3,500+ (2024) |
| Logistics cost/patient | 8–12% (~$40k–$60k) |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Legend Biotech outlining customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure and governance, reflecting its CAR-T cell therapy commercialization strategy and R&D pipeline; designed for investor presentations with integrated competitive analysis, SWOT-linked insights and actionable implications for strategic and financial decision-making.
Customizable Excel Spreadsheet
High-level view of Legend Biotech’s business model with editable cells to quickly map CAR-T development, partnerships, and revenue pathways—ideal for boardrooms, team collaboration, and fast executive summaries.
Activities
Cell Therapy Manufacturing
Legend Biotech runs specialized GMP manufacturing sites that convert patient T-cells into autologous CAR-T therapies using viral transduction and CRISPR-edited steps, with batch-level release testing and potency assays to meet FDA and EMA standards.
By Q4 2025 Legend expanded U.S. and EU capacity to >30,000 treatments/year and invested ~$420 million in facilities and automation to cut vein-to-vein time to ~3–4 weeks.
Clinical Development and Trials
Legend Biotech runs continuous clinical development to advance CAR-T therapy ciltacabtagene autoleucel (cilta-cel) into earlier lines for multiple myeloma, running pivotal and registrational trials—over 1,200 patients enrolled across studies by end-2025—and aims to expand label and market reach. Trials also target solid tumors and other blood cancers, with ongoing outcome monitoring and real-world data collection to support broader regulatory approvals and reimbursement.
Research and Platform Innovation
Legend Biotech invests >$400M annually in CAR-T and cell therapy R&D (2024 SEC filing), advancing autologous bb2121 successors and exploring allogeneic off-the-shelf candidates to cut manufacturing time and cost; binder tech and cell engineering upgrades aim to improve efficacy and reduce relapse rates, supporting a pipeline of 10+ programs as of Dec 31, 2024.
Commercial Strategy and Marketing
Legend Biotech coordinates with partners to run targeted medical-education campaigns, present at ASH and EHA (attended 2023–2025), and publish in journals like NEJM and Blood to highlight efficacy and safety of cilta-cel; in 2024 commercial uptake contributed to Janssen-partnered sales reported at $310M global product revenue.
Here’s the quick math: >60 congress presentations 2023–2025, 15 peer-reviewed papers, and commercial positioning aimed at relapsed/refractory multiple myeloma where overall response rates exceeded 70% in pivotal studies.
- Partner-led HCP education at ASH/EHA
- 15+ peer-reviewed papers (2023–2025)
- 70%+ ORR in pivotal trials
- $310M 2024 product revenue (Janssen partnership)
Regulatory and Quality Compliance
Legend Biotech must follow Good Manufacturing Practices and global health rules to keep licenses; in 2024 the FDA cited biologics makers in 7% of warning letters, making ongoing audits and batch-release checks critical.
Teams continuously audit facilities and submit safety reports (e.g., IND/BCSRs) to regulators to prevent recalls; compliance lapses can stop production and erode physician and patient trust.
- Maintain GMP-certified sites and QMS
- Perform routine internal and external audits
- File timely safety reports to FDA and EMA
- Track KPIs: audit findings, CAPA closure time
- Mitigate production halt risk—costs can exceed $10M+ per month
Scaling autologous CAR‑T: >30k treatments/yr, $420M capex, registrational trials & commercial rollout
Operate GMP sites for autologous CAR-T (cilta-cel), run registrational trials and R&D, maintain QMS/compliance, and coordinate commercial/medical affairs to drive uptake and label expansion.
| Metric | Value |
|---|---|
| 2025 Capacity | >30,000 treatments/yr |
| Capital spend | ~$420M |
| R&D spend (2024) | >$400M |
| Patients enrolled | ~1,200 (end‑2025) |
| 2024 Revenue (Janssen) | $310M |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual Legend Biotech Business Model Canvas—not a mockup or sample—and it matches exactly the file you’ll receive after purchase, ready for immediate use.
